Single-cell atlas of CD19 CAR T cells provide a public resource to drive insights into B cell lymphoma
Many patients with relapsed/refractory (R/R) large B cell lymphoma respond well to chimeric antigen receptor (CAR) T cell therapy targeting CD19. Still, most do not have a durable response, highlighting a need to understand the underlying resistance mechanisms. To address this issue, researchers led by Qing Deng, Ph.D., Michael Green, Ph.D., and Xubin Li, Ph.D., used single-cell RNA sequencing to establish a large dataset of CAR T cells to treat 59 patients with R/R large B cell lymphoma. To show...











